Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Antineoplastic Agents, Phytogenic
  • Antineoplastic Combined Chemotherapy Protocols
  • Brain Neoplasms
  • Camptothecin
  • Glioblastoma

abstract

  • We conclude that single-agent bevacizumab has significant biologic and antiglioma activity in patients with recurrent glioblastoma.

publication date

  • February 10, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2645088

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.16.3055

PubMed ID

  • 19114704

Additional Document Info

start page

  • 740

end page

  • 5

volume

  • 27

number

  • 5